These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2883131)

  • 1. Application of histamine-induced conjunctivitis to the assessment of a topical antihistamine, levocabastine.
    Feinberg G; Stokes TC
    Int Arch Allergy Appl Immunol; 1987; 82(3-4):537-8. PubMed ID: 2883131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid onset of action of levocabastine eye-drops in histamine-induced conjunctivitis.
    Stokes TC; Feinberg G
    Clin Exp Allergy; 1993 Sep; 23(9):791-4. PubMed ID: 10779311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model.
    Netland PA; Leahy C; Krenzer KL
    Am J Ophthalmol; 2000 Dec; 130(6):717-23. PubMed ID: 11124289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis.
    Dechant KL; Goa KL
    Drugs; 1991 Feb; 41(2):202-24. PubMed ID: 1709851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effect of levocabastine on experimental allergic conjunctivitis in guinea pigs.
    Kamei C; Izushi K; Tasaka K
    J Pharmacobiodyn; 1991 Aug; 14(8):467-73. PubMed ID: 1723098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
    Abelson MB; Greiner JV
    Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a new selective H1 receptor antagonist (levocabastine) in a nasal and conjunctival provocation test.
    Pécoud A; Zuber P; Kolly M
    Int Arch Allergy Appl Immunol; 1987; 82(3-4):541-3. PubMed ID: 2883132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The early efficacy of topical levocabastine in patients with allergic conjunctivitis.
    Fujishima H; Fukagawa K; Takano Y; Okamoto S; Nakagawa Y; Uchio E; Yokoi N; Fukushima A; Takamura E
    Allergol Int; 2006 Sep; 55(3):301-3. PubMed ID: 17075271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levocabastine eye drops: a new approach for the treatment of acute allergic conjunctivitis.
    Abelson MB; Weintraub D
    Eur J Ophthalmol; 1994; 4(2):91-101. PubMed ID: 7950341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical levocabastine protects better than sodium cromoglycate and placebo in conjunctival provocation tests.
    Rimås M; Kjellman NI; Blychert LO; Björkstén B
    Allergy; 1990 Jan; 45(1):18-21. PubMed ID: 1968726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levocabastine: a new topical approach for the treatment of paediatric allergic rhinoconjunctivitis.
    Janssens MM
    Rhinol Suppl; 1992 Sep; 13():39-49. PubMed ID: 1358140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical levocabastine, a selective H1 antagonist, in seasonal allergic rhinoconjunctivitis.
    Bende M; Pipkorn U
    Allergy; 1987 Oct; 42(7):512-5. PubMed ID: 2891316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ophthalmic levocabastine for allergic conjunctivitis.
    Med Lett Drugs Ther; 1994 Apr; 36(920):35-6. PubMed ID: 7908401
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of levocabastine in conjunctival provocation studies.
    Janssens M
    Doc Ophthalmol; 1992; 82(4):341-51. PubMed ID: 1363980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the new ophthalmic antihistamine, 0.05% levocabastine, in the clinical allergen challenge model of allergic conjunctivitis.
    Abelson MB; George MA; Schaefer K; Smith LM
    J Allergy Clin Immunol; 1994 Sep; 94(3 Pt 1):458-64. PubMed ID: 7916020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of effects of topical levocabastine and nedocromil sodium on the early response in a conjunctival provocation test with allergen.
    Hammann C; Kämmerer R; Gerber M; Spertini F
    J Allergy Clin Immunol; 1996 Dec; 98(6 Pt 1):1045-50. PubMed ID: 8977503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levocabastine: an effective topical treatment of allergic rhinoconjunctivitis.
    Janssens MM; Vanden Bussche G
    Clin Exp Allergy; 1991 May; 21 Suppl 2():29-36. PubMed ID: 1680536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind evaluation of topical levocabastine, a new specific H1 antagonist in patients with allergic conjunctivitis.
    Pipkorn U; Bende M; Hedner J; Hedner T
    Allergy; 1985 Oct; 40(7):491-6. PubMed ID: 2866725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use.
    Yanni JM; Stephens DJ; Parnell DW; Spellman JM
    J Ocul Pharmacol; 1994; 10(4):665-75. PubMed ID: 7714410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis.
    Noble S; McTavish D
    Drugs; 1995 Dec; 50(6):1032-49. PubMed ID: 8612470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.